Our retrospective cohort, drawn from a 60,000-case specialised HF registry, provides the first clinical dataset demonstrating short-term benefits in LVEF, 6-min walk distance, NT-proBNP, and patient-reported outcomes. This evidence concerns the gene NPPB and hydrops fetalis.